McKesson (MCK) 10-K Summaries & Annual Filing History
Review McKesson Corporation (MCK) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Mar 31, 2026 · FY2026 10-K
McKesson Corporation is a diversified healthcare services leader that partners with biopharma companies, care providers, pharmacies, and governments to make quality care more accessible and affordable. The company reported revenue growth for the fiscal year ended March 31, 2026, with operating income, net income, and operating cash flow all positive.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$403.4B
Revenue reported for the fiscal year.
Operating income
$6.2B
Income from operations reported for the year.
Net income
$4.8B
Net income reported for the year.
Operating cash flow
$6.2B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $276.7B | +4.8% |
| Mar 31, 2024 | $309B | +11.7% |
| Mar 31, 2025 | $359.1B | +16.2% |
| Mar 31, 2026 | $403.4B | +12.4% |
Business overview
McKesson operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company traces its roots to 1833 and is incorporated in Delaware, with a fiscal year ending March 31. It provides insights, products, and services to help improve health outcomes globally.
Financial performance
Revenue increased compared to the prior fiscal year, continuing a multi-year upward trend. Operating income, net income, and operating cash flow were all reported as positive figures for the period. The company's financial direction reflects sustained growth in revenue and profitability.
Material risks
The filing references risk factors but does not provide specific details in the supplied context. The company operates in a highly regulated industry, and its business is subject to government regulation. Competition is noted as a factor across its segments.
Liquidity and capital
Cash, cash equivalents, and restricted cash decreased compared to the prior year, while working capital remained negative. The debt-to-capital ratio increased, indicating higher leverage relative to equity.
What to watch
Monitor changes in the debt-to-capital ratio and working capital position in the next filing.